Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
NCT05508009
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the risk of chronic rejection and, ultimately, the need for repeated transplantation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SIOD
- Cystinosis
- FSGS
- SLE Nephritis
- CKD Stage 4
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 1 year to 30 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alice Bertaina
- Last updated on ClinicalTrials.gov
- July 17, 2023
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Lucile Packard Children's Hospital · Palo Alto, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.